Loading
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Previous close
$14.66
+$0.21 · +1.45%
After-hours
$14.66
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Day range
Current $14.66
52-week range
Current $14.66
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
74
Undervalued
Sentiment
76
Bullish
Risk
61
High Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Day range
Current $14.66
52-week range
Current $14.66
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 102.48M USD | 62.04M USD | 153.73M USD | 67.77M USD | 61.88M USD |
| Cost of goods sold | 7.32M USD | 7.22M USD | 6.82M USD | 8.29M USD | 9.77M USD |
| Gross profit | 95.16M USD | 54.83M USD | 146.92M USD | 59.48M USD | 52.11M USD |
| Research and development | 166.42M USD | 252.04M USD | 180.43M USD | 137.17M USD | 104.4M USD |
| Selling, general, and administrative | 41.02M USD | 48.45M USD | 62.58M USD | 59.54M USD | 56M USD |
| Operating expenses | 200.11M USD | 293.28M USD | 236.19M USD | 188.43M USD | 150.63M USD |
| Interest income | 9.25M USD | 44.43M USD | 14.51M USD | 3.46M USD | 577K USD |
| Interest expense | 38.21M USD | 31.07M USD | 23.75M USD | 3.35M USD | 3.14M USD |
| Depreciation and amortization | 7.32M USD | 7.22M USD | 6.82M USD | 5.69M USD | 4.84M USD |
| Operating income | −104.95M USD | −238.45M USD | −89.28M USD | −128.94M USD | −98.52M USD |
| Net income | −191.09M USD | −227.46M USD | −106.79M USD | −119.2M USD | −105.54M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$51.00
247.89% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 3, 2025 | 1:10 | — | — |
Effective Dec 3, 2025
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.15M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM5.53M0.01%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF3.63M0.00%95.4B USD0.05%$233.49-1.56%
Fidelity Enhanced Small Cap ETFFESM2.28M0.03%6.41B USD0.28%$45.22-1.14%
Vanguard Russell 2000 ETFVTWO1.85M0.01%18B USD0.06%$112.21-1.26%
Vanguard Health Care ETFVHT922.4K0.00%22B USD0.09%$315.31+0.78%
iShares Micro-Cap ETFIWC651.17K0.05%1.33B USD0.60%$183.36-1.09%
iShares Core S&P Total U.S. Stock Market ETFITOT426.17K0.00%98.16B USD0.03%$169.28-0.37%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
